TLTaehyeong Lim

Taehyeong Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taehyeong Lim has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing Gingerol-Based Analogs against Pseudomonas aeruginosa Infections

    by Taehyeong Lim, Soyoung Ham, Han-Shin Kim, Ji-Eun Yang, Hyunwoong Lim, Hee-Deung Park, Youngjoo Byun

    Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative opportunistic pathogen, produces virulent factors and forms biofilms through a quorum sensing (QS) mechanism. Modulating QS networks is considered an effective strategy for treating P. aeruginosa infections. Particularly, the rhl system, one of the QS networks, can be a potential target in treating patients with chronic infections. We previously discovered that gingerol acts as a RhlR antagonist of P. aeruginosa. Based on the chemical structure of gingerol, we have designed and synthesized gingerol derivatives by introducing various functional groups in the middle and tail regions. A comprehensive structure-activity relationship study showed that compound 5a substituted with phenyl group in the tail region was the most potent in various biological assessments, such as RhlR binding affinity, rhl gene expression, and virulence factor production of P. aeruginosa. Furthermore, compound 5a decreased the biofilm formation and pathogenicity of P. aeruginosa. Interestingly, compound 5a also influenced las system in addition to the rhl system. Taken together, compound 5a can be utilized as a potent compound for controlling P. aeruginosa infection.


  • Open Access

    Recent Advance in Small Molecules Targeting RhlR of Pseudomonas aeruginosa

    by Taehyeong Lim, So-Young Ham, SangJin Nam, Myoungsun Kim, Ki Yong Lee, Hee-Deung Park, Youngjoo Byun

    Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic gram-negative pathogen that can cause various infections, particularly in patients with compromised host defenses. P. aeruginosa forms biofilms and produces virulence factors through quorum sensing (QS) network, resulting in resistance to antibiotics. RhlI/RhlR, one of key QS systems in P. aeruginosa, is considered an attractive target for inhibiting biofilm formation and attenuating virulence factors. Several recent studies examined small molecules targeting the RhlI/RhlR system and their in vitro and in vivo biological activities. In this review, RhlR-targeted modulators, including agonists and antagonists, are discussed with particular focus on structure-activity relationship studies and outlook for next-generation anti-biofilm agents.


  • Open Access

    TNP and its analogs: Modulation of IP6K and CYP3A4 inhibition

    by Seulgi Lee, Bernie Byeonghoon Park, Hongmok Kwon, Vitchan Kim, Jang Su Jeon, Rowoon Lee, Milan Subedi, Taehyeong Lim, Hyunsoo Ha, Dongju An, et al.

    Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.


  • Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature

    by Hyunsoo Ha, Hongmok Kwon, Taehyeong Lim, Jaebong Jang, Song-Kyu Park, Youngjoo Byun

    Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...